Mobile

A clinical study to determine how the drug CC-122 works in the body and to see if it is safe and if it works, when given alone, or in combination with Ibrutinib, or in combination with Obinutuzumab, f...

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-003056-31

A clinical study to determine how the drug CC-122 works in the body and to see if it is safe and if it works, when given alone, or in combination with Ibrutinib, or in combination with Obinutuzumab, for people who have Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

- Determine the safety of single agent CC-122 in subjects with relapsed/refractory CLL/SLL - Determine the safety and tolerability of the combination of CC-122 and ibrutinib and determine the RP2D of the combination in ibrutinib-naive CLL/SLL subjects - Determine the safety and tolerability of the combination of CC-122 and obinutuzumab and determine the RP2D of the combination in subjects with relapsed/refractory CLL/SLL

Critère d'inclusion

  • Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) based on modified International Workshop on Chronic Lymphocytic Leukemia (IWCLL)

Liens